The direct inhibitory effect of dutasteride or finasteride on androgen receptor activity is cell line specific

Prostate

Volumn 73, Issue 14, 2013, Pages 1483-1494

  Chhipa, Rishi Raj ^a   Halim, Danny ^a,b   Cheng, Jinrong ^a   Zhang, Huan Yi ^a   Mohler, James L ^a,c   Ip, Clement ^a   Wu, Yue ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b PADJADJARAN UNIVERSITY   (Indonesia)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

androgen receptor signaling; antiandrogen; dutasteride; finasteride; prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; DUTASTERIDE; FINASTERIDE; LUCIFERASE;

ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL GROWTH; CELL PROTECTION; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; GENOTYPE; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; PRIORITY JOURNAL;

ANDROGEN RECEPTOR SIGNALING; ANTIANDROGEN; DUTASTERIDE; FINASTERIDE; PROSTATE CANCER;

5-ALPHA REDUCTASE INHIBITORS; ANIMALS; AZASTEROIDS; CATTLE; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL PROLIFERATION; DIHYDROTESTOSTERONE; FINASTERIDE; GENE EXPRESSION REGULATION; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84883163775     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22696     Document Type: Article

References (40)

1. Mohler JL, Titus MA, Wilson EM,. Potential prostate cancer drug target: Bioactivation of androstanediol by conversion to dihydrotestosterone. Clin Cancer Res 2011; 17 (18): 5844-5849.
2. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS,. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362 (13): 1192-1202.
3. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes D, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA,. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349 (3): 215-224.
4. Wu Y, Chhipa RR, Zhang H, Ip C,. The antiandrogenic effect of finasteride against a mutant androgen receptor. Cancer Biol Ther 2011; 11 (10): 902-909.
5. Sobel RE, Sadar MD,. Cell lines used in prostate cancer research: A compendium of old and new lines-Part 1. J Urol 2005; 173 (2): 342-359.
6. Sobel RE, Sadar MD,. Cell lines used in prostate cancer research: A compendium of old and new lines-Part 2. J Urol 2005; 173 (2): 360-372.
7. Wu Y, Fabritius M,., Ip C,. Chemotherapeutic sensitization by endoplasmic reticulum stress: Increasing the efficacy of taxane against prostate cancer. Cancer Biol Ther 2009; 8 (2): 146-152.
8. Cheng J, Wu Y, Mohler JL,., Ip C,. The transcriptomics of de novo androgen biosynthesis in prostate cancer cells following androgen reduction. Cancer Biol Ther 2010; 9 (12): 1033-1042.
9. Yeh S, Chang C,. Cloning and characterization of a specific coactivator, ARA 70, for the androgen receptor in human prostate cancer cells. Proc Natl Acad Sci USA 1996; 93 (11): 5517-5521.
10. Kokontis J, Ito K, Hipakka RA, Liao S,. Expression and function of normal and LNCaP androgen receptors in androgen-insensitive human prostatic cancer cells. Altered hormone and antihormone specificity in gene transactivation. Receptor 1991; 1 (4): 271-279.
11. Tan J, Sharief Y, Hamil KG, Gregory CW, Zang DY, Sar M, Gumerlock PH, deVere White RW, Pretlow TG, Harris SE, Wilson EM, Mohler JL, French FS,. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 1997; 11 (4): 450-459.
12. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S,. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab 2004; 89 (5): 2179-2184.
13. Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT,. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res 2006; 12 (13): 4072-4079.
14. Suzuki R, Satoh H, Ohtani H, Hori S, Sawada Y,. Saturable binding of finasteride to steroid 5alpha-reductase as determinant of nonlinear pharmacokinetics. Drug Metab Pharmacokinet 2010; 25 (2): 208-213.
15. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann AO, Mulder E,. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990; 173 (2): 534-540.
16. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balik SP,. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995; 332 (21): 1393-1398.
17. Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley GJ, Balik SP,. Functional characterization of mutant androgen receptors from androgen-independent prostat cancer. Clin Cancer Res 1997; 3 (8): 1383-1388.
18. Gottlieb B, Beitel LK, Nadarajah A, Paliouras M, Trifiro M,. The androgen receptor gene mutations database: 2012 update. Hum Mutat 2012; 33 (5): 887-894.
19. Balk SP,. Androgen receptor as a target in androgen-independent prostate cancer. Urology 2002; 60 (Suppl. 3A): 132-139.
20. Bergerat JP, Çraline J,. Pleiotropic functional properties of androgen receptor mutants in prostate cncer. Hum Mutat 2009; 30 (2): 145-157.
21. Heinlein CA, Chang C,. Androgen receptor in prostate cancer. Endocrine Rev 2004; 25 (2): 276-308.
22. Steinkamp MP, O'Mahony OA, Brogley M, Rehman H, LaPensee EW, Dhanasekaran S, Hofer MD, Keufer R, Chinnaiyan A, Rubin MA, Pienta KJ, Robins DM,. Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res 2009; 69 (10): 4434-4442.
23. Yuan X, Balik SP,. Mechanisms mediating androgen receptor reactivation after castration. Urol Oncol 2009; 27 (1): 36-41.
24. Andrieu T, Bertolini R, Nichols SE, Setoud R, Frey FJ, Baker ME, Frey BM,. A novel steroidal antiandrogen targeting wild type and mutant androgen receptors. Biochem Pharmacol 2012; 82 (11): 1651-1662.
25. Arnold JT, Liu X, Allen JD, Le H, McFann KK, Blackman MR,. Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells. Prostate 2007; 67 (11): 1152-1162.
26. Cherian MT, Wilson EM, Shapiro DJ,. A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes. J Biol Chem 2012; 287 (28): 23368-23380.
27. Makkonen H, Kauhanen M, Jaaskelainen T, Palvimo JJ,. Androgen receptor amplification is reflected in the transcriptional responses of vertebral-cancer of the prostate cells. Mol Cell Endocrinol 2011; 331 (1): 57-65.
28. McCourt C, Maxwell P, Mazzucchelli R, Montironi R, Scareplli M, Salto-Tellez M, O'Sullivan JM, Longley DB, Waugh DJ,. Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy. Clin Cancer Res 2012; 18 (14): 3822-3833.
29. Seaton A, Scullin P, Maxwell PJ, Wilson C, Pettigrew J, Gallagher R, O'Sullivan JM, Johnston PG, Waugh DJ,. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Carcinogenesis 2008; 29 (6): 1148-1156.
30. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL,. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10 (9): 33-39.
31. Sun C, Xu LL, Nageswararao C, Davis LD, Segawa T, Dobi A, McLeod DG, Srivastava S,. Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival. Oncogene 2006; 25 (28): 3905-3913.
32. Schmidt LJ, Tindall DJ,. Steroid 5 alpha-reductase inhibitors targeting BPH and prostate cancer. J Steroid Biochem Mol Biol 2011; 125 (1-2): 32-38.
33. Lazier CB, Thomas LN, Douglas RC, Vessey JP, Rittmaster RS,. Dutasteride, the dual 5α-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line. Prostate 2004; 58 (2): 130-144.
34. Chhipa RR, Lee KS, Onate S, Wu Y, Ip C,. Prx1 enhances androgen receptor function in prostate cancer cells by increasing receptor affinity to dihydrotestosterone. Mol.Cancer Res 2009; 7 (9): 1543-1552.
35. Fang Y, Fliss AE, Robins DM, Caplan AJ,. Hsp90 regulates androgen receptor hormone binding affinity in vivo. J Biol Chem 1996; 271 (45): 28697-28702.
36. Zoubeidi A, Zardan A, Beraldi E, Fazli L, Sowery R, Rennie P, Nelson C, Gleave M,. Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res 2007; 67 (21): 10455-10465.
37. Gioeli D, Paschal BM,. Post-translational modification of the androgen receptor. Mol Cell Endocrinol 2012; 352 (1-2): 70-78.
38. Chang GTG, Blok LJ, Steenbeek M, Veldscholte J, van Weerden WM, van Steenbrugge GJ, Brinkmann AO,. Differentially expressed genes in androgen-dependent and -independent prostate carcinomas. Cancer Res 1997; 57 (18): 4075-4081.
39. Guillemettte C, Hum DW, Belanger A,. Evidence for a role of glucuronosyltransferase in the regulation of androgen action in the human prostatic cancer cell line LNCaP. J Steroid Biochem Mol Biol 1996; 57 (3-4): 225-231.
40. Barbier O, Belanger A,. Inactivation of androgens by UDP- glucuronosyltransferases in the human prostate. Best Practice Res Clin Endocrinol Metab 2008; 22 (2): 259-270.